The information regarding this deal has been sourced from an SEC filing published on February 26, 2026, retrieved from SEC EDGAR. The specific form type is not identified in the available documentation. The deal is currently pending regulatory approval and has not yet closed.
On the financial advisory side, Wells Fargo Bank, National Association has been engaged by Boston Scientific Corp, the acquirer, to serve as administrative agent for the financing arrangement. Wells Fargo holds a lead position in this capacity. No other financial advisors have been identified in the available source materials for either the borrower or the lender syndicate.
No legal advisors have been identified or disclosed in the source documentation reviewed for this transaction.
The deal structure comprises two credit facilities: a revolving credit facility and a delayed draw term loan. Both facilities are being provided to Boston Scientific Corp as the borrower by multiple lenders coordinated through Wells Fargo Bank, National Association in its administrative agent capacity. However, the specific terms of these facilities, including tenor, pricing, interest rate mechanics, commitment amounts, or any other quantitative details, have not been disclosed in the source documents.
Several material terms and structural details remain undisclosed or unknown at this time. The aggregate transaction value is not stated in any reviewed source material. The tenor, spread, base rate, and pricing terms of both the revolving credit facility and the delayed draw term loan have not been specified. The identity of the lending syndicate members beyond the administrative agent, as well as any lead arranger or book manager roles, is not disclosed. Additionally, no expected closing date or timeline for regulatory approval has been provided. The consideration structure for the acquisition itself, including whether it is being funded entirely through these credit facilities or through other means, is not specified in the available documentation.